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Background: Brainstem encephalitis is a serious complication of hand foot and mouth disease (HFMD) in children.
Autonomic nervous system (ANS) dysregulation and hypertension may occur, sometimes progressing to cardiopulmonary
failure and death. Vietnamese national guidelines recommend use of milrinone if ANS dysregulation with Stage 2
hypertension develops. We wished to investigate whether magnesium sulfate (MgSO4) improved outcomes in children
with HFMD if used earlier in the evolution of the ANS dysregulation (Stage 1 hypertension).
Methods: During a regional epidemic we conducted a randomized, double-blind, placebo-controlled trial of MgSO4 in
children with HFMD, ANS dysregulation and Stage 1 hypertension, at the Hospital for Tropical Diseases in Ho Chi Minh
city. Study participants received an infusion of MgSO4 or matched placebo for 72 h. We also reviewed data from non-trial
HFMD patients in whom milrinone failed to control hypertension, some of whom received MgSO4 as second line therapy.
The primary outcome for both analyses was a composite of disease progression within 72 h - addition of milrinone (trial
participants only), need for ventilation, shock, or death.
Results: Between June 2014 and September 2016, 14 and 12 participants received MgSO4 or placebo respectively, before
the trial was stopped due to futility. Among 45 non-trial cases with poorly controlled hypertension despite high-dose
milrinone, 33 received MgSO4 while 12 did not. There were no statistically significant differences in the composite
outcome between the MgSO4 and the placebo/control groups in either study (adjusted relative risk (95%CI) of [6/14
(43%) vs. 6/12 (50%)], 0.84 (0.37, 1.92), p = 0.682 in the trial and [1/33 (3%) vs. 2/12 (17%)], 0.16 (0.01, 1.79), p = 0.132 in the
observational cohort). The incidence of adverse events was similar between the groups. Potentially toxic magnesium
levels occurred very rarely with the infusion regime used.
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Conclusion: Although we could not demonstrate efficacy in these studies, there were no safety signals associated with
use of 30-50mg/kg/hr. MgSO4 in severe HFMD. Intermittent outbreaks of HFMD are likely to continue across the region,
and an adequately powered trial is still needed to evaluate use of MgSO4 in controlling hypertension in severe HFMD,
potentially involving a higher dose regimen.
Trial registration: ClinicalTrials.gov Identifier: NCT01940250 (Registered 22 AUG 2013).
Trial sponsor: University of Oxford
Keywords: Hand foot and mouth disease, Brainstem encephalitis, Autonomic nervous system dysregulation,
Hypertension, Magnesium sulfate, Clinical trialBackground
Over the last 15 years hand, foot and mouth disease
(HFMD) has become an increasingly important cause of
paediatric morbidity and mortality in Vietnam, and has
placed a huge burden on healthcare services across the
Asia-Pacific region [1]. During outbreaks thousands of
young children can be affected, and while HFMD is typic-
ally mild and self-limited, severe complications do occur,
albeit rarely. Most notably, brainstem encephalitis may
develop, presenting with autonomic nervous system (ANS)
dysregulation around the third or fourth day of fever,
sometimes with severe hypertension that may progress to
cause cardiopulmonary failure [2]. Typically, the period of
ANS dysregulation lasts for 48-72 h, although in severe
cases progression may be rapid, with death occurring
within a few hours.
Management of ANS dysregulation in children presents
particular challenges. A phosphodiesterase inhibitor,
milrinone, has become the recommended therapy for
severe HFMD, based on findings from two small studies,
one retrospective, involving 65 participants overall, that re-
ported benefit with milrinone in patients with cardiopulmo-
nary failure [3, 4]. For children with HFMD and ANS
dysregulation, current Vietnamese Ministry of Health
(MoH) guidelines recommend close observation without
anti-hypertensive therapy when the systolic blood pressure
(SBP) remains between the 95th percentile and 5mmHg
above the 99th percentile for age (i.e Stage 1 hypertension
[5]), but to intervene promptly (ideally within 1 h) with mil-
rinone when the SBP exceeds the 99th centile for age plus
5mmHg, (i.e. Stage 2 hypertension [5]). However, despite
use of high dose milrinone in accordance with these recom-
mendations, some children continue to deteriorate, rapidly
requiring ventilatory support and/or haemofiltration [6].
Safety data regarding milrinone use in children are limited,
although associations with tachyarrhythmias and acute
renal failure have been documented [7, 8].
Tetanus is another disease in which ANS dysregulation
with severe hypertension occurs. Extrapolating from re-
search in adults with tetanus [9–11], and from experience
in rare conditions such as phaeochromocytoma [12, 13],
magnesium sulfate (MgSO4) has become the drug of choiceto control ANS dysregulation in neonates with tetanus
managed on the Paediatric Intensive Care Unit (PICU) at
the Hospital for Tropical Diseases (HTD) in Ho Chi Minh
City, using a regimen of 30–50mg/kg per hour for up to 7
days titrated according to response [14]. The physiological
rationale underlying use of MgSO4 in these circumstances
relies on several properties of magnesium (Mg) ions: they
compete with calcium (Ca) ions for receptors on vascular
smooth muscle cells and can influence BP by modulating
vascular tone [15]; Mg has an important role in the classical
pathway of nitric oxide (NO) release, with changes in extra-
cellular Mg content modifying production and release of
NO and thereby altering arterial tone [16]; Mg also de-
creases the release of catecholamines after sympathetic
stimulation [17]. MgSO4 is cheap, readily available and
easily neutralised, and is therefore generally considered to
be safe although little formal safety data is available for chil-
dren [18–20]. Given the experience with neonatal tetanus,
when a major outbreak of HFMD commenced across the
region in 2011 and use of high-dose milrinone proved inad-
equate to control ANS dysregulation in several cases,
MgSO4 was adopted at HTD as second line treatment with
promising initial results [21].
We hypothesized that intervention with MgSO4 early,
when hypertension due to ANS dysregulation first be-
comes apparent, might control cardiovascular instability
more effectively and prevent progression to severe disease.
In June 2014 we commenced a randomized, double-blind,
placebo-controlled intervention trial to evaluate the effi-
cacy and safety of MgSO4 in 190 children with HFMD,
ANS dysregulation and Stage 1 hypertension [19]. How-
ever, over the next 2 years the number of HFMD cases
seen across Vietnam declined dramatically, and by the end
of 2016 the trial was stopped on the grounds of futility.
Over the 18-month period needed to obtain funding
and the necessary ethical approvals to commence the
trial, open-label MgSO4 was often used to treat severe
cases. We therefore reviewed the hospital files of all
non-trial severe HFMD cases managed on PICU from
2011 onwards to identify those who had received open-
label MgSO4, aiming to gather additional data on the
efficacy and safety of MgSO4 in severe HFMD, in the
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continue across the region in the coming years.
Methods
The clinical trial
This was a randomized, double-blind, placebo-controlled
trial of intravenous MgSO4 versus placebo in Vietnamese
children with a clinical diagnosis of Grade 3 HFMD (ac-
cording to guidelines issued by the Vietnamese MoH [22])
and signs of ANS dysregulation including systemic hyper-
tension. The study was approved by the ethics committees
of HTD and the Vietnamese MoH, as well as the Oxford
University Tropical Research Ethics Committee, and was
carried out in strict compliance with all ICH-GCP guide-
lines and recommendations. The trial was registered with
ClinicalTrials.gov (NCT01940250), and the full protocol
has been published [23].
Essential details of the general study methodology are
presented in Additional file 1: Appendix A, and the Viet-
namese grading system for HFMD is summarised in Add-
itional file 2: Table S1. In brief, patients aged 6months to
15 years admitted to PICU at HTD with a clinical diagnosis
of Grade 3 HFMD were eligible for enrolment if the BP,
measured invasively, was sustained above the cut-off for
Stage 1 hypertension (i.e. the 95th centile for age, gender
and length [24]) for at least 30min while the child was not
distressed, and the individual exhibited at least one other
criterion of ANS dysregulation. Children presenting with
Stage 2 hypertension were also eligible for enrolment pro-
vided they had no evidence of acute target organ damage,
with the proviso that study treatment must commence
within 30min of admission and that milrinone should be
added within a further 30min if there was no improvement
– ie the total time to commencing milrinone should be 1 h
if the child did not improve (see Additional file 1: Appen-
dix A for further information). An explanation of the Viet-
namese guidelines for treatment of severe HFMD was
given to the parent/guardian, together with specific infor-
mation on the proposal to intervene with either MgSO4 or
placebo when their child would not usually receive specific
therapy for hypertension and details of the systems in place
to commence specific treatment with milrinone within 1 h
should this be necessary. Following written informed con-
sent by the parent/guardian, study participants were ran-
domly allocated in a 1:1 ratio to receive a loading dose of
50mg/kg of either 10% MgSO4 (Fresenius Kabi, Germany)
or visually matched placebo. The study drug was given as a
continuous infusion over 20min followed by a mainten-
ance infusion of 30–50mg/kg/hr. for 72 h according to re-
sponse, aiming for plasma total Mg levels between 1.8 and
2.5mmol/l in the treatment arm. Recognizing that having a
child in ICU is extremely stressful, detailed information on
the study protocol was presented to the family a second
time within 12–24 h of enrolment, in order to be sure thatthey had fully understood the information presented earl-
ier. At this time the option to withdraw from the study was
again clearly articulated to the parent/guardian.
All staff involved in clinical care were blind to the
treatment allocation, and Mg levels were monitored and
adjusted by independent doctors from another clinical
facility; these doctors focused particularly on safety,
especially given that children in the active arm were
receiving an antihypertensive agent at an earlier stage
than usual. Detailed clinical assessments were performed
daily, with vital signs documented at least hourly for the
first 72 h and full biochemical profiles and ECGs per-
formed at least once daily. Catecholamine levels, specif-
ically adrenaline and noradrenaline, were measured on
plasma and urine specimens collected daily for 3 days
after study enrolment between 8 and 10 am. All clinical
and laboratory adverse events were graded following the
CTCAE Version 4.03 guidelines [25], modified for chil-
dren (Additional file 1: Appendix A.7, A.8).
The primary endpoint was a composite of disease pro-
gression defined as occurrence of any of the following
within 72 h of commencing the study drug: pre-specified
BP criteria necessitating addition of milrinone in accord-
ance with MoH guidelines for HFMD with Stage 2 hyper-
tension; ventilation; shock; or death. Secondary outcomes
included the time to requirement for milrinone, the area
under the curve (AUC) for heart rate (HR), systolic blood
pressure (SBP), and mean arterial pressure (MAP) above
the Stage 1 hypertension level during the first 72 h, the
duration of hospitalization, and neurodevelopmental sta-
tus assessed 6months after discharge [26].
The observational cohort
Using HTD’s electronic patient database, we identified the
hospital files of all children with HFMD who received mil-
rinone between January 2011 and December 2015. From
these files we identified cases where the BP remained above
the Stage 2 hypertension level despite high dose milrinone
(0.6–0.7 μg/kg/minute) but without cardiovascular decom-
pensation at that time (see Additional file 1: Appendix B
for details). We wished to compare responses in terms of
hemodynamic stability and severe outcomes in patients
who fulfilled these criteria and received MgSO4, with simi-
lar cases who achieved the same basic cardiovascular sever-
ity level but for whom MgSO4 was not used. All available
data on clinical progress, management and outcomes were
extracted from the hospital files to a special case report
form (CRF) and entered into an electronic database. The
MgSO4 regimen used in the exposed patient group was
nominally the same as that used in the trial. The primary
outcome was a composite including development of shock,
respiratory compromise requiring ventilation, or death, oc-
curring within the first 72 h from time zero – i.e. the time
when MgSO4 was actually introduced (exposed group), or
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dividual’s cardiovascular status (control group). Secondary
outcomes included the AUC for SBP and MAP above the
Stage 1 hypertension level over 24 h from time zero, (since
subsequent blood pressure monitoring was less detailed
than in the trial), and the duration of hospitalization.
Statistical analysis
Summary statistics are absolute count and percentage for
categorical variables and median (range) for continuous
data. For the trial, in view of the small number of patients
enrolled we only performed the intention-to-treat analysis.
For both the trial and the observational study, between-
group comparisons for the primary outcome of disease
progression were based on log-binomial regression models
(generalized linear models for binomial outcome and
using log link function) with adjustment for age and day
of illness at study entry/time zero.
For the trial secondary outcomes, the time from com-
mencement of study drug to addition of milrinone was
compared using the log-rank test and a Cox proportional
hazards model with adjustment for baseline SBP and day of
illness at study entry. Patients who never received milri-
none were censored at 72 h. Between-group comparisons
of the AUCs for the various cardiovascular parameters were
based on linear regression models with adjustment for the
baseline value of the variable of interest. As AUCs for SBP
and MAP were skewed to the right, we log10-transformed
these variables before applying regression analysis. For the
neurodevelopmental assessments, Z scores for each domain
were derived for each individual using data from healthy
Vietnamese children matched by age group [26]. We then
calculated mean differences in these Z scores between the
intervention groups using linear regression and adjusting
for age, sex and maternal education level. For comparison
of the catecholamine profiles, we used a linear mixed
effects regression model that accounted for the evolution of
the responses in the two groups.
In the observational study, the group of children who
did not receive MgSO4 were generally hospitalised
during the early period of the outbreak, thus forming a
historical control group for those who received MgSO4
later. For the exposed group, decision-making regarding
when to commence MgSO4 appeared to be influenced
by the patient’s age, the rapidity of the deterioration, and
the experience of the clinician, in addition to the specific
BP criteria outlined above and in Additional file 1: Ap-
pendix B. We therefore developed a logistic regression
model for initiation of MgSO4 for each time point at
which SBP was measured in the exposed group. We then
used this model to impute a time at which MgSO4 could
have been initiated for each set of observations for the
control patients. We produced 20 imputed datasets and
performed comparisons similar to those described abovefor the clinical trial on each dataset, finally combining
the results using Rubin’s rule [27] and a modified rule
that accounted for differences in size between imputed
datasets. Detailed information describing these proce-
dures is provided in Additional file 1: Appendix B,
Additional file 3: Tables S2, Additional file 4: Table S3 and
Additional file 5: Table S4.
Results
The clinical trial
Between June 2014 and September 2016, 59 children
with Grade 3 HFMD and signs of ANS dysregulation
underwent screening for potential inclusion in the trial,
of whom 26 (MgSO4 = 14, Placebo = 12) were enrolled
following written consent by a parent or guardian (Fig. 1,
Panel a). Compliance with all aspects of the study proto-
col was excellent, with only a small number of minor
protocol deviations. All trial participants received the
designated study drug according to the randomization
code, and 23/26 cases completed the full 72-h infusion
as per protocol. The study drug was unblinded in 3
cases. One child in the placebo group developed emer-
gency hypertension (Additional file 1: Appendix A.3);
after unblinding showed that the child was allocated to
the placebo arm, open label MgSO4 was commenced,
following which the BP settled without additional ther-
apy. The two other children developed severe respiratory
distress requiring ventilation; one child was in the pla-
cebo group, with Mg/total calcium (Ca) levels within the
normal range, while the other was in the active interven-
tion arm, with plasma Mg and Ca levels of 2.3 and 1.9
mmol/l respectively.
Clinical and laboratory characteristics were similar at
baseline between the MgSO4 and placebo groups (Table 1),
except that the proportion of children with Stage 2 hyper-
tension was considerably greater in the placebo group (8/
12, 67%) than in the MgSO4 group (3/14, 21%). Enterovi-
ruses were detected by generic RT-PCR [28] in 18/26 (70%)
of the cases overall, which is within the same range as pre-
vious reports for clinically diagnosed HFMD [29, 30], with
EV-A71 confirmed by specific RT-PCR [31] in 9/14 (64%)
MgSO4 recipients and 4/12 (33%) placebo recipients.
No patient died or developed shock, while 6/12 (50%)
cases in the placebo group required milrinone compared
to 6/14 (43%) cases in the MgSO4 group. Two children
who received milrinone also required ventilation, one in
each treatment group. There was no significant differ-
ence in the composite primary outcome between the
two groups, adjusted relative risk (95%CI) 0.84 (0.37,
1.92), p = 0.682 (Table 2). There was also no significant
difference in the time from study drug initiation to
addition of milrinone between the treatment groups
(Table 2, Panel A and Fig. 2). Evaluation of the AUCs
for the various cardiovascular parameters showed each
a b
Fig. 1 Patient recruitment and study group allocation in the clinical trial (Panel a) and the observational cohort (Panel b). Abbreviations:
HTD – Hospital for Tropical Diseases, HTN – hypertension, IBP- Invasive Blood Pressure
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were no statistically significant differences (Table 3).
Plasma catecholamine levels were generally elevated or
at the upper end of the expected normal ranges for chil-
dren at study enrolment (Additional file 6: Figure S1),
falling progressively over the 3 days period of observa-
tion. However, there were no significant differences in
the overall profiles between the study arms (p = 0.609
and p = 0.997, respectively, for plasma adrenaline and
noradrenaline levels). Urine catecholamine levels were
also increased at enrolment, fell progressively over time,
and were generally lower in the MgSO4 group compared
to the placebo group at each timepoint, but with no
statistically significant differences overall (p = 0.545 and
p = 0.589, respectively, for urine adrenaline and nor-
adrenaline levels).
A total of 21 clinical adverse events (AEs) occurred in
10 patients in the placebo group (83%) compared to 22
events in 10 children in the MgSO4 group (71%)
(Table 4). Serious clinical AEs occurred in 5 patients
overall. Respiratory distress developed in 2 patients in
the placebo group and 3 in the MgSO4 group, with one
patient in each group requiring ventilation. In no casewere the AEs or SAEs associated with Mg levels in ex-
cess of 3 mmol/l (maximum recorded value, 2.72 mmol/
l), the usual threshold of concern for respiratory or CNS
depressant effects of hypermagnesaemia. Laboratory ab-
normalities were common but were observed with simi-
lar frequencies in the two study arms.
All participants were well enough for discharge by
study day 14, although 3 children had persisting clinic-
ally apparent neurological problems: two with general-
ized weakness and one with 9th and 11th cranial nerve
palsies. However, all three had recovered by the 6-
month follow-up visit, at which time all study partici-
pants had normal neurological and neurodevelopmental
assessments (see Additional file 3: Table S2).
The observational cohort
From January 2011 to December 2015, 165 children with
severe HFMD were treated with milrinone (Fig. 1, Panel
b). Among the 103 children who received high dose mil-
rinone for Stage 2 hypertension, 45 cases where the BP
remained poorly controlled were selected for detailed
study; 33 received MgSO4 (the exposed group) while 12
did not (the control group). The baseline characteristics
Table 1 Baseline information for the clinical trial population
Placebo (N = 12) MgSO4 (N = 14)
Demographic and clinical features
Age (months) 21 (7, 57) 24 (9, 73)
Sex (female) 6 (50) 9 (64)
Weight (kg) 11 (7, 19) 11 (7, 20)
Illness day at enrolment 3.5 (1.0, 6.0) 3.0 (2.0, 5.0)
Fever (> 37.5 °C) 12 (100) 13 (93)
Mouth ulcers present 10 (83) 11 (79)
Skin lesions present 9 (75) 11 (79)
Skin ANS featuresa 2 (17) 1 (7)
Tachycardiab 2 (17) 1 (7)
SBP (mmHg) 116 (105, 129) 113 (101, 134)
DBP (mmHg) 61 (52, 73) 59 (47, 73)
Stage of hypertension
Stage1 4 (33) 11 (79)
Stage2 8 (67) 3 (21)
Tachypnea 5 (42) 6 (43)
Irregular breathing 7 (58) 5 (36)
Respiratory retractions 1 (8) 3 (21)
Irritability 4 (33) 1 (7)
Neurological abnormalitiesc 3 (25) 0 (0)
Laboratory investigations
Arterial blood gases
- pH 7.44 (7.40, 7.59) 7.41 (7.36, 7.48)
- pCO2 (mmHg) 29.8 (18.6, 35.7) 33.3 (29.4, 40.1)
Hb (g/dl) 11.8 (8.8, 15.2) 11.8 (6.4, 14.3)
WBC (× 109/l) 10.2 (4.6, 15.5) 13.6 (5.5, 26.5)
CK-MB (IU/l) 23.4 (10.4, 64.8) 25.4 (13.8, 48.1)
Troponin I (pg/ml) 5 (0, 20) 5 (0, 27)
Mg (mmol/l) 0.85 (0.70, 0.99) 0.88 (0.78, 0.98)
Ca (mmol/l) 2.28 (1.69, 2.52) 2.31 (1.95, 2.42)
Na (mmol/l) 131 (126, 134) 131 (125, 136)
Creatinine (μmol/l) 26 (17, 52) 27 (18, 42)
Blood sugar (mmol/l) 5.4 (4.0, 7.6) 5.7 (5.0, 8.1)
Lab-confirmed EV infection 7 (58) 11 (78)
EV-A71 positive 4 (33) 9 (64)
Other EV positived 3 (25) 2 (14)
Summary statistic is absolute count (%) for categorical variables and median
(range) for continuous data
SBP Systolic blood pressure, DBP Diastolic blood pressure, EV-A71 Enterovirus
A71, EV Enterovirus
aSkin manifestations of autonomic nervous system (ANS) dysregulation
bTachycardia: Heart rate sustained > 150 beats/min, adjusted down by 10 for
each 1 degree of fever above 37.0
cMyoclonic jerks were noted in 2 cases, while limb tremor/ataxia and
nystagmus were present in 1 case, all in the placebo group
dIncludes 3 cases of Coxsackievirus (CV) A16, 1 case of CV A10, 1 case of CV –
C, all other cases were negative
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dren in the MgSO4 group were significantly older than the
controls and EV-A71 was identified less frequently in the
MgSO4 recipients, (23/33 (70%) compared to 12/12 (100%))
(Table 5). Of note, 11 of the 12 children in the control
group were admitted in the early stage of the outbreak when
EV-A71 was known to be prevalent, whereas later the pat-
tern of serotypes in circulation became more diverse [32].
Ten deaths occurred within the specified time period,
nine in 2011 and one in 2012. Six patients developed se-
vere hypertension and deteriorated very rapidly before
reaching the maximum dose of milrinone, and none of
the 10 patients fulfilled the selection criteria for this ana-
lysis. In the selected study population, no child died or
progressed to shock, although three children, two con-
trols and one MgSO4 recipient, required ventilation.
There was no significant difference in the primary out-
come between the MgSO4 and control groups (relative
risk (95%CI) of 0.16 (0.01, 1.79), p = 0.132) (Table 2,
Panel B). Similarly, we found no difference in the AUCs
for SBP and MAP above the Stage 1 hypertension level
between the groups (Table 3).
Therapeutic monitoring
In both patient groups that received MgSO4, plasma Mg
levels increased within a few hours. Almost all trial partici-
pants achieved levels in the desired therapeutic range (1.8
to 2.5 mmol/l), within the first 12 h (Fig. 3). However, Mg
levels were generally lower in the observational cohort;
although the treatment regimen was nominally the same
in both groups, the peak infusion rate (median, IQR)
achieved for the trial participants was 50 (40, 50) mg/kg/
hr. compared to 40 (30, 50) mg/kg/hr. in the observational
cohort. A total of 7/130 (5%) Mg levels measured in the
MgSO4 recipients in the trial were in the 2.5–3mmol/l
range, resulting in a recommendation by the independent
safety monitoring doctor to reduce the dose in 6 cases. In
the observational cohort, 2 Mg levels were documented in
the 2.5–3mmol/l range, plus a single high value of 3.13
mmol/l. However, this child had no respiratory problems,
the ECG was normal, and the Mg level dropped promptly
to the therapeutic range following dose reduction.
The median Ca levels in the MgSO4 group decreased
from 2.28 mmol/l at baseline to a minimum of 1.85
mmol/l on Day 1 then increased again to 2.13 mmol/l on
Day 3, demonstrating a reciprocal relationship with the
Mg levels (Fig. 3). In total 32 Ca values, including 20 in
the observational study MgSO4 group, 11 in the trial
MgSO4 group and 1 in the placebo group, were docu-
mented below the level of 1.8 mmol/l (equivalent to an
ionised Ca2+ level of 0.9 mmol/l, i.e. the threshold for
potential concern), with the lowest recorded value of
1.55 mmol/l. No clinical AEs linked to low Ca levels oc-
curred and no interventions were required.
Table 2 Primary and secondary endpoints observed in the different treatment groups in both studiesa
Panel A: Clinical Trial Panel B: Observational Cohort
Placebo
(N = 12)
MgSO4
(N = 14)
Estimated effect
(95% CI)
p-value Control
(N = 12)
MgSO4
(N = 33)
Estimated
effect (95% CI)
p-value
Primary endpointb 6 (50%) 6 (43%) 0.84 (0.37, 1.92) 0.682 2 (17%) 1 (3%) 0.16 (0.01, 1.79) 0.132
Requirement for ventilation 1 (8%) 1 (7%) – 2 (17%) 1 (3%) 0.16 (0.01, 1.79) 0.132
Requirement for milrinone 6 (50%) 6 (43%) 0.80 (0.25, 2.55) 0.706 – – –
Time to start of milrinonec 1.6 (0.6, 19.5) 2.0 (1.2, 3.8) – – –
Length of hospitalizationc 5 (5, 6) 5 (5, 6) 0.12 (−1.55, 1.79) 0.889 9 (8, 13) 9 (7, 10) −1.65 (−3.79, 0.49) 0.117
The estimated effect for the primary endpoint and for requirement for ventilation is the relative risk, while for length of hospitalization it is the mean difference,
and for requirement for milrinone it is the hazard ratio
Results are based on log-binomial regression (primary endpoint, requirement for ventilation), linear regression (length of hospitalization), Cox regression
(requirement for milrinone). For those patients who never received milrinone the nominal start time was fixed at 72 h. All analyses were adjusted for age and
illness day (except for Cox regression analysis which was adjusted for illness day and systolic blood pressure at baseline)
aPanel A for the clinical trial and Panel B for the observational cohort
bFor the clinical trial the primary endpoint was a composite outcome of death or shock or requirement for ventilation or need for milrinone, while for the
observational cohort it comprised death or shock or requirement for ventilation (since all study participants were already on milrinone)
cLength of hospitalization and time to start of milrinone are summarized in terms of median (range) values. Length of hospitalization is the number of days from
study enrolment to hospital discharge. Time to start of milrinone is the number of hours from initiation of study drug to addition of milrinone, and is only
described for patients who received milrinone
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Therapeutic options for severe HFMD remain limited [1, 3,
4], despite the rapidly increasing burden of disease in the
southeast Asian region over the last two decades, and the
life-threatening nature of the clinical syndromes seen in a
small proportion of cases [33–37]. In this report we present
the findings from two studies examining the efficacy and
safety of intravenous MgSO4 for management of ANS
related hypertension in children with HFMD complicated
by brainstem encephalitis.
Regrettably, the first study, a formal randomized
double-blind placebo-controlled clinical trial, had to
be stopped on the grounds of futility after enrolment
of only 26 of the planned 190 cases when theFig. 2 Kaplan-Meier curves showing the time from baseline to addition ofregional epidemic of HFMD waned after 2014. Base-
line information was similar between the two treat-
ment arms, except that a greater proportion of
children in the placebo group presented with more
severe (Stage 2) hypertension. Conversely, EV-A71,
the serotype generally associated with more severe
outcomes [38, 39], predominated in the MgSO4
group. These differences between the treatment arms
are likely to be random and related to the small num-
ber of participants recruited [40], but there is the po-
tential for an impact on the outcomes of interest.
With respect to efficacy, although we observed minor
differences in the findings for a number of outcomes,
generally favoring the MgSO4 group, there were nomilrinone in the clinical trial
Table 3 Effect of MgSO4 on selected hemodynamic parameters in the clinical trial and the observational cohort
Placebo / Controla MgSO4 Mean difference (95% CI) p-value
Clinical Trial (for 72 h from study drug initiation) (N = 12) (N = 14)
AUC of HR (beats/min x hr)
Median (range) 9728 (8820, 10,983) 9021 (8156, 11,008)
Mean (sd) 9816 (744) 9296 (931) − 581 (− 1264, 102) 0.095
Log-10 AUC of SBP above stage 1 HTN (log10(mmHg x hr))
Median (range) 2.52 (1.80, 3.22) 2.40 (1.48, 3.09)
Mean (sd) 2.46 (0.39) 2.36 (0.47) −0.07 (− 0.40, 0.27) 0.701
Log-10 AUC of MAP above stage 1 HTN (log10(mmHg x hr))
Median (range) 2.16 (1.00, 3.04) 2.13 (0.00, 2.69)
Mean (sd) 2.09 (0.63) 2.03 (0.68) 0.05 (−0.45, 0.55) 0.850
Observational cohort (for 24 h from study drug initiation) (N = 12) (N = 33)
Log-10 AUC of SBP above stage 1 HTN (mmHg x hr)b
Median (range) 2.47 (1.82, 2.87) 2.50 (1.54, 2.83)
Mean (sd) 2.44 (0.31) 2.42 (0.33) −0.05 (−0.26, 0.15) 0.604
Log-10 AUC of MAP above stage 1 HTN (mmHg x hr)b
Median (range) 1.54 (0.00, 2.74) 1.62 (0.00, 2.56)
Mean (sd) 1.62 (0.72) 1.54 (0.57) −0.17 (−0.54, 0.19) 0.354
Note: In the clinical trial the study drug was commenced at Stage 1 hypertension without milrinone, while in the observational cohort MgSO4 was commenced at
Stage 2 hypertension when the patients were already on high dose milrinone
Comparisons for AUCs of HR, SBP and MAP were based on linear regression with adjustment for their corresponding values at baseline
HR Heart rate, SBP Systolic blood pressure, MAP Mean arterial pressure, AUC Area under the curve, HTN Hypertension, sd standard deviation
aPlacebo Group in the clinical trial and Control Group in the observational cohort
bFor the control group, results are based on multiple imputation of the time that MgSO4 would have commenced. The imputation model is a logistic regression
model based on: a) the difference between the current SBP and the age-dependent cut-off for Stage 2 hypertension; b) the difference between the current SBP
and the previous SBP value; and c) the current dose of milrinone. The descriptions were averaged across imputation datasets while the comparisons were based
on Rubin’s rule (a modified rule to take into account difference in size between imputed datasets gave similar results). Detailed information describing this
methodology can be found in the Additional file 1, Additional file 3: Table S2, Additional file 4: Table S3 and Additional file 5: Table S4
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ary outcomes evaluated in the trial. However, given the
small number of patients enrolled and the low event
rate, no conclusions can be drawn. The initial pilot data
had suggested an effect in patients with Stage 2
hypertension who were already on milrinone [21], and
it is possible that among the less severe cases enrolled
in the formal clinical trial, any potential beneficial ef-
fects were diluted.
More patients were included in the observational co-
hort analysis than in the clinical trial, but the final re-
sults also showed no statistically significant difference in
the primary or secondary endpoints between those pa-
tients who did and did not receive MgSO4. However, the
differences we noted between the two groups – i.e. older
age and a lower proportion of participants with EV-71
infection in the exposed than the control group – are
both typically associated with less severe disease out-
comes and may be confounders. In addition, the patients
included in the observational cohort were generally
more severe at baseline than those enrolled in the clin-
ical trial (Stage 2 versus Stage 1 hypertension), and theMg levels were generally lower than the levels achieved
in the trial. In studies of MgSO4 use in other conditions,
the target therapeutic level has varied from 2mmol/l to
5.5 mmol/l [10, 19, 41]. For the trial we selected a target
range of 1.8–2.5 mmol/l, with most patients achieving
the upper end of this range early on. By contrast, more
than half the patients in the observational cohort who
received MgSO4 did not achieve the 1.8 mmol/l lower
margin, most likely because this was a new intervention
in very sick children and clinicians were more cautious
during the first year until they developed confidence that
serious toxicity did not occur. Thus, it is possible that a
therapeutic effect might have been demonstrated had we
aimed for higher Mg levels.
Limited data are currently available regarding MgSO4
safety profiles in children [14, 19, 42], or the relation-
ship between different therapeutic regimens and mea-
sured Mg and Ca levels. Our data are important in
showing that potentially toxic Mg levels very rarely oc-
curred using 30–50 mg/kg/hr. in sick children. Also,
use of this regimen resulted in consistent plasma Mg
levels with reciprocal plasma Ca responses in most
Table 4 Adverse events observed in the two treatment arms in
the clinical trial
Number of patients with
event
Placebo
(n = 12)
MgSO4
(n = 14)
Clinical events
All adverse eventsa 21 / 10 (83) 22 / 10
(71)
Fever 6 7
Diminished deep tendon reflexes 2 3
Coma / lethargy / irritability 2 1
Respiratory problems 3 4
Reduced urine output (< 1 ml/kg/hr for
4 h)
4 5
Otherb,c 4 2
Serious adverse events (Grades 3 and 4)a 3 / 2 (17) 3 / 3 (21)
Coma 1 0
Respiratory distress 2 3
Laboratory events
All adverse eventsa 46 / 12
(100)
51 / 13
(93)
Respiratory Acidosis 0 3
Respiratory Alkalosis 8 6
Abnormal CK-MB 7 9
Abnormal Creatinine 2 2
Abnormal Hb 4 4
Hyperkalemia 2 0
Hypokalemia 5 2
Hyponatremia 9 9
Abnormal Troponin I 5 5
Serious adverse events (Grades 3 and 4)a 16 / 8 (67) 21 / 10
(71)
Respiratory Acidosis 0 1
Respiratory Alkalosisd 3 6
Abnormal CK-MB 1 0
Abnormal Hb 1 0
Hypokalemia 1 1
Hyponatremiae 5 7
Abnormal Troponin I 5 4
Adverse events were graded using the CTCAE Version 4.03 system, modified
for children
aNumbers are total events / events grouped by patient (% of patients in the
group with any events)
bPlacebo group: 2 with generalised erythema, 1 diarrhoea, 1 measles
cMgSO4 group: 1 case each of vomiting and myoclonic jerks
dIn all cases respiratory alkalosis occurred in spontaneously breathing patients
eSevere hyponatremia developed in patients not receiving concurrent
intravenous fluids
Table 5 Clinical and laboratory features in the observational
cohort for the MgSO4 exposed and control groups
a
MgSO4 (N = 33) Control (N = 12)
Demographic and clinical featuresb
Age (months) 36 (12, 153) 15 (6, 45)
Sex (female) 7 (21) 6 (50)
Weight (kg) 18 (9, 55) 10 (7, 20)
Illness day at T = 0 4 (2, 8) 4 (1, 7)
Fever (> 37.50 C) 26 (79) 11 (92)
Skin ANS featuresc 1 (3) 0 (0)
Tachycardiad 7 (21) 2 (17)
Systolic BP at T = 0 140 (122, 200) 134 (119, 168)
Diastolic BP at T = 0 70 (55, 110) 64 (54, 88)
Tachypnea for age 16 (55) 9 (75)
Irregular breathing 3 (12) 2 (18)
Neurological abnormalitiese 1 (3) 0 (0)
Laboratory investigationsb
Hb (g/dl) 11.9 (9.1, 14.9) 13.1 (9.0, 15.0)
WBC (×109/l) 12.0 (5.7, 17.7) 12.6 (9.9, 26.7)
CK-MB (IU/l) 23.9 (11.7, 71.7) 36.8 (17.5, 159.2)
Troponin I (pg/ml) 11 (00, 48) 13 (0, 772)
Blood sugar (mmol/l) 5.9 (4.2, 9.1) 5.7 (4.2, 10.9)
Lab-confirmed EV infection 25 (76) 12 (100)
EV-A71 positive 23 (70) 12 (100)
Other EV positivef 2 (6) 0
Summary statistic is absolute count (%) for categorical variables and median
(range) for continuous data
aFeatures assessed within the 24 h before the actual/potential time to start
MgSO4 (T = 0)
bMissing data for tachypnea in 4 cases in the MgSO4 group. For the lab
investigations data were missing in less than 5% of cases for most variables,
except that CK-MB and Troponin were only measured in patients with
tachycardia sustained > 170 bpm (MgSO4 Group – 18 cases, Control group –
6 cases)
cSkin manifestations of autonomic nervous system (ANS) dysregulation
dTachycardia: Heart rate sustained > 150 beats/min, adjusted down by 10 for
each 1oC of fever above 37.0 °C
eMyoclonic jerks were not observed during the 24 h before T = 0 in any
patient, while limb tremor/ataxia was present in 1 case in the MgSO4
exposed group
fIncluding 1 case with Coxsackievirus (CV) A 16, 1 case with an undefined
enterovirus, all other cases PCR negative
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monitoring may not be necessary in the absence of
clinical concerns suggesting toxicity. However, should
more aggressive regimens be adopted in future studies,
aiming to investigate efficacy at higher plasma Mg
levels, regular monitoring of plasma levels would still
be required.
Conclusions
To summarize, in these two studies we found no clear
evidence of benefit but a dose of 30-50 mg/kg/hr.
Fig. 3 Combined data for the serial Magnesium/Calcium levels in the clinical trial and the observational cohort. Legends: In the observational
cohort Mg/Ca levels were only measured in patients receiving MgSO4. Black bar = median value; n = number of patients assessed. Dashed green
line: Potentially toxic levels for hypermagnesemia and hypocalcemia. D0 = baseline values, Mid-point = values measured 8–16 h after commencing
the study drug. Other values (D1, D2, D3) were measured at 8–10 am on the relevant study day. By study day 3 a number of the trial patients had
completed 72 h of the intervention and were already being weaned off their study drug. Patients in the observational cohort generally stopped
MgSO4 after 48 h
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However, it is apparent that these data are not sufficient
to address the hypothesis originally posed. The question
of whether MgSO4 could be optimized as first line ther-
apy remains an important one, and an adequately pow-
ered trial is still needed to properly evaluate its role in
controlling hypertension in severe HFMD. Epidemio-
logical observations over the last 20–30 years suggest
that ongoing outbreaks of HFMD are likely to occur
intermittently across the region in the coming years. To
facilitate clinical research during epidemics of infectious
disease advance preparation is crucial. The experience
gained from these studies, both the general experience
of setting up and conducting a complex trial on sick
children during a major outbreak, and the more particu-
lar information regarding the positive safety profile of
MgSO4 used in this way plus the information generated
on dosing in relation to plasma Mg/Ca levels, should
prove invaluable when the next epidemic occurs.
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